subscribeSubscribe
Immunic Receives Notice of Allowance for Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus

Immunic Receives Notice of Allowance for Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus
PR NEWSWIRE
02 Nov 2023
Share Share
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium
PR NEWSWIRE
16 Oct 2023
Share Share
Immunic Completes Enrollment of Phase 2 CALLIPER Trial of Vidofludimus Calcium

Immunic Completes Enrollment of Phase 2 CALLIPER Trial of Vidofludimus Calcium
PR NEWSWIRE
17 Aug 2023
Share Share
Immunic touts positive data in maintenance phase of failed PhII trial, pulls back asset

Immunic touts positive data in maintenance phase of failed PhII trial, pulls back asset
Paul Schloesser ENDPTS
07 Apr 2023
Share Share
Immunic Reports Positive Data from PII CALDOSE-1 Trial of Vidofludimus Calcium

Immunic Reports Positive Data from PII CALDOSE-1 Trial of Vidofludimus Calcium
PR NEWSWIRE
05 Apr 2023
Share Share
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium
PR NEWSWIRE
22 Feb 2023
Share Share
Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium
PRNEWSWIRE
17 Nov 2022
Share Share
Immunic regains some momentum with multiple sclerosis update

Immunic regains some momentum with multiple sclerosis update
N.P. Taylor FIERCEBIOTECH
16 Jun 2022
Share Share
Immunic shares cut in half as biotech dumps ulcerative colitis after PhII fail

Immunic shares cut in half as biotech dumps ulcerative colitis after PhII fail
P. Schloesser ENDPTS
04 Jun 2022
Share Share
Immunic Reports Top-Line Data from PII CALDOSE-1 Trial of Vidofludimus Calcium

Immunic Reports Top-Line Data from PII CALDOSE-1 Trial of Vidofludimus Calcium
PRNEWSWIRE
02 Jun 2022
Share Share